Geode Capital Management LLC Has $15.55 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Geode Capital Management LLC lifted its position in Perspective Therapeutics, Inc. (NYSE:CATX) by 12.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,164,204 shares of the company’s stock after acquiring an additional 129,654 shares during the period. Geode Capital Management LLC owned approximately 1.72% of Perspective Therapeutics worth $15,546,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC raised its position in shares of Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after purchasing an additional 5,370,392 shares during the period. Nicholson Wealth Management Group LLC acquired a new stake in Perspective Therapeutics during the 3rd quarter worth approximately $21,390,000. State Street Corp lifted its stake in Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after buying an additional 1,192,812 shares in the last quarter. Hills Bank & Trust Co acquired a new position in shares of Perspective Therapeutics in the third quarter valued at approximately $13,722,000. Finally, Ally Bridge Group NY LLC bought a new stake in shares of Perspective Therapeutics during the second quarter worth $3,951,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Trading Down 3.0 %

Shares of NYSE CATX opened at $3.19 on Monday. The company has a 50 day simple moving average of $6.86 and a 200 day simple moving average of $10.76. Perspective Therapeutics, Inc. has a 1 year low of $2.70 and a 1 year high of $19.05.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The company had revenue of $0.37 million for the quarter. As a group, research analysts expect that Perspective Therapeutics, Inc. will post -0.88 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CATX has been the topic of several research reports. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price objective (down from $20.00) on shares of Perspective Therapeutics in a research report on Thursday, November 21st. Royal Bank of Canada cut their price target on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a report on Monday, November 25th. UBS Group began coverage on Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 price objective for the company. Oppenheimer reduced their price target on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, November 22nd. Finally, Truist Financial started coverage on shares of Perspective Therapeutics in a report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price on the stock. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $15.14.

Insider Buying and Selling

In other Perspective Therapeutics news, Director Heidi Henson purchased 25,975 shares of the stock in a transaction dated Wednesday, December 4th. The shares were bought at an average price of $3.85 per share, with a total value of $100,003.75. Following the completion of the transaction, the director now directly owns 25,975 shares in the company, valued at approximately $100,003.75. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Johan M. Spoor purchased 8,000 shares of Perspective Therapeutics stock in a transaction dated Wednesday, December 4th. The stock was bought at an average price of $3.77 per share, with a total value of $30,160.00. Following the completion of the transaction, the chief executive officer now owns 36,257 shares of the company’s stock, valued at $136,688.89. This represents a 28.31 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have bought 67,570 shares of company stock valued at $256,789. 3.52% of the stock is owned by company insiders.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.